^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | ZL-1211 (CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Published date:
09/07/2022
Excerpt:
Here, we report that ZL-1211 is a mAb targeting CLDN18.2 engineered to promote enhanced antibody-dependent cellular cytotoxicity (ADCC) with the goal of achieving more potent activity in a wider spectrum of high- and low-CLDN18.2 expressing tumors. ZL-1211 demonstrated more robust in vitro ADCC activity than clinical benchmark not only in CLDN18.2-high but also CLDN18.2-low expressing gastric tumor cell lines. Greater antitumor efficacy was also observed in mouse xenograft models.
DOI:
10.1158/2767-9764.CRC-22-0216
Source:
Title:
1203-ZL-1211 exhibits broad anti-tumor activity in CLDN18.2 high- and low-expressing models
Published date:
03/10/2021
Excerpt:
Here we present ZL-1211, a novel CLDN18.2-targeting monoclonal antibody that was engineered to promote enhanced ADCC and to drive efficacy in tumors that exhibit a broad range of CLDN18.2 expression levels....Consistent with our in vitro findings, ZL-1211 also exhibited greater anti-tumor efficacy than the leading clinical benchmark in CLDN18.2-positive patient-derived xenograft and syngeneic models in vivo.
